SpringWorks [SWTX] vs Blueprint Medicines [BPMC] Detailed Stock Comparison
SpringWorks
NASDAQ
Loading...
Blueprint Medicines
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 18 vital metrics comparison: SpringWorks wins in 6 metrics, Blueprint Medicines wins in 11 metrics, with 0 ties. Blueprint Medicines appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | SpringWorks | Blueprint Medicines | Better |
|---|---|---|---|
| P/E Ratio (TTM) | N/A | -120.99 | N/A |
| Price-to-Book Ratio | 8.44 | 24.43 | SpringWorks |
| Debt-to-Equity Ratio | 1.77 | 208.50 | SpringWorks |
| PEG Ratio | -21.96 | -137.72 | Blueprint Medicines |
| EV/EBITDA | -12.49 | -53.14 | Blueprint Medicines |
| Profit Margin (TTM) | -115.60% | -27.70% | Blueprint Medicines |
| Operating Margin (TTM) | -164.07% | -27.50% | Blueprint Medicines |
| Return on Equity | -51.57% | -47.71% | Blueprint Medicines |
| Return on Assets (TTM) | -28.47% | -9.75% | Blueprint Medicines |
| Free Cash Flow (TTM) | $-196.30M | $-197.22M | SpringWorks |
| 1-Year Return | 27.79% | 12.60% | SpringWorks |
| Price-to-Sales Ratio (TTM) | 16.12 | 14.89 | Blueprint Medicines |
| Enterprise Value | $3.26B | $8.42B | Blueprint Medicines |
| EV/Revenue Ratio | 14.84 | 14.97 | SpringWorks |
| Gross Profit Margin (TTM) | 92.81% | 98.12% | Blueprint Medicines |
| Revenue per Share (TTM) | $3 | $9 | Blueprint Medicines |
| Earnings per Share (Diluted) | $-3.41 | $-2.51 | Blueprint Medicines |
| Beta (Stock Volatility) | 0.70 | 0.83 | SpringWorks |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
SpringWorks vs Blueprint Medicines Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| SpringWorks | 0.00% | 0.04% | 0.69% | 1.01% | 30.24% | 30.24% |
| Blueprint Medicines | 0.00% | 0.12% | 1.05% | 53.79% | 15.63% | 48.46% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| SpringWorks | 27.79% | 61.20% | 22.37% | 107.64% | 107.64% | 107.64% |
| Blueprint Medicines | 12.60% | 149.54% | 73.38% | 370.76% | 598.65% | 598.65% |
Performance & Financial Health Analysis: SpringWorks vs Blueprint Medicines
| Metric | SWTX | BPMC |
|---|---|---|
| Market Information | ||
| Market Cap | $3.54B | $8.37B |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 4,023,957 | 5,799,940 |
| 90 Day Avg. Volume | 4,304,692 | 4,343,357 |
| Last Close | $46.99 | $129.46 |
| 52 Week Range | $28.21 - $62.00 | $73.04 - $129.65 |
| % from 52W High | -24.21% | -0.15% |
| All-Time High | $96.48 (Feb 08, 2021) | $129.65 (Jul 16, 2025) |
| % from All-Time High | -51.30% | -0.15% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 1.34% | 0.56% |
| Quarterly Earnings Growth | 1.34% | -0.99% |
| Financial Health | ||
| Profit Margin (TTM) | -1.16% | -0.28% |
| Operating Margin (TTM) | -1.64% | -0.28% |
| Return on Equity (TTM) | -0.52% | -0.48% |
| Debt to Equity (MRQ) | 1.77 | 208.50 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $5.57 | $5.30 |
| Cash per Share (MRQ) | $3.82 | $8.92 |
| Operating Cash Flow (TTM) | $-165,428,000 | $-145,552,000 |
| Levered Free Cash Flow (TTM) | $-94,371,752 | $-20,779,750 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: SpringWorks vs Blueprint Medicines
| Metric | SWTX | BPMC |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | N/A | -120.99 |
| Forward P/E | -21.96 | -137.72 |
| PEG Ratio | -21.96 | -137.72 |
| Price to Sales (TTM) | 16.12 | 14.89 |
| Price to Book (MRQ) | 8.44 | 24.43 |
| Market Capitalization | ||
| Market Capitalization | $3.54B | $8.37B |
| Enterprise Value | $3.26B | $8.42B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 14.84 | 14.97 |
| Enterprise to EBITDA | -12.49 | -53.14 |
| Risk & Other Metrics | ||
| Beta | 0.70 | 0.83 |
| Book Value per Share (MRQ) | $5.57 | $5.30 |
Financial Statements Comparison: SpringWorks vs Blueprint Medicines
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | SWTX | BPMC |
|---|---|---|
| Revenue/Sales | $49.09M | $149.41M |
| Cost of Goods Sold | $3.53M | $2.80M |
| Gross Profit | $45.56M | $146.61M |
| Research & Development | $49.60M | $91.89M |
| Operating Income (EBIT) | $-80.54M | $-41.09M |
| EBITDA | $-81.09M | $23.55M |
| Pre-Tax Income | $-83.19M | $1.29M |
| Income Tax | N/A | $789,000 |
| Net Income (Profit) | $-83.19M | $496,000 |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | SWTX | BPMC |
|---|---|---|
| Cash & Equivalents | $63.77M | $122.25M |
| Total Current Assets | $356.32M | $702.07M |
| Total Current Liabilities | $82.27M | $250.58M |
| Long-Term Debt | $5.69M | $409.17M |
| Total Shareholders Equity | $417.40M | $342.13M |
| Retained Earnings | $-1.24B | $-2.41B |
| Property, Plant & Equipment | $25.83M | $97.66M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | SWTX | BPMC |
|---|---|---|
| Operating Cash Flow | $-46.37M | $13.41M |
| Capital Expenditures | N/A | $-1.83M |
| Free Cash Flow | $-68.79M | $-56.31M |
| Debt Repayment | N/A | $-4.11M |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | SWTX | BPMC |
|---|---|---|
| Shares Short | 6.38M | 3.13M |
| Short Ratio | 1.46 | 0.62 |
| Short % of Float | 0.10% | 0.05% |
| Average Daily Volume (10 Day) | 4,023,957 | 5,799,940 |
| Average Daily Volume (90 Day) | 4,304,692 | 4,343,357 |
| Shares Outstanding | 74.40M | 63.71M |
| Float Shares | 74.16M | 60.00M |
| % Held by Insiders | 0.01% | 0.01% |
| % Held by Institutions | 0.87% | 1.09% |
Dividend Analysis & Yield Comparison: SpringWorks vs Blueprint Medicines
| Metric | SWTX | BPMC |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |